Suzhou Basecare Medical Corp. Ltd. Reports 18.8% Decrease in Revenue to RMB101.3 Million for First Half of 2025

Reuters
09/25
Suzhou Basecare Medical Corp. Ltd. Reports 18.8% Decrease in Revenue to RMB101.3 Million for First Half of 2025

Suzhou Basecare Medical Corp. Ltd. reported its interim results for the six months ended June 30, 2025. Revenue for the period was RMB101.3 million, representing a decrease of 18.8% compared to RMB124.7 million in the same period last year. The company's net assets decreased to RMB1,031.7 million from RMB1,141.8 million as of the previous period. During the reporting period, Suzhou Basecare generated revenue from the sales of testing kits, testing and cryopreservation devices and instruments, embryo culture devices, embryo culture solution, consumables, and other products. The company stated that it continues to focus on developing AI-driven innovations in assisted reproduction, including the advancement of its "AI+Reproduction" platform and the iARMS intelligent management system. Suzhou Basecare plans to accelerate global promotion of new products and enhance penetration in the domestic market, supported by international brand partnerships and the local healthcare policy environment. The company will leverage AI to upgrade laboratory scenarios across genetics, andrology, embryos, and cryopreservation, aiming to drive competitiveness and growth in both domestic and international markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Basecare Medical Corp. Ltd. published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10